company
About Us
Management Team
Board of Directors
Advisory Board
pipeline
Overview
Tissue Fibrosis
Endometriosis
Oncology
NEWS
Contact
Pipeline
.
First-in-Class Drugs
.
Indication
Preclinical
Ph.1
Ph.2a
Ph.2b
Ph.3
Postoperative Tissue Fibrosis
TTX333
OB-GYN
General
Surgery
Endometriosis
TTX334e
Endometriosis
Oncology
TTX335o
Ovarian
Cancer
Product
Target & MOA
Indication
Preclinical
Ph.1
Ph.2a
Ph.2b
Ph.3
NDA Filing
NDA Approval
Postoperative Tissue Fibrosis
TTX333
HIF1-a
OB-GYN
Intra-Operative
Instillation (IP)
TTX333
HIF1-a
General Surgery Intra-Operative Instillation (IP)
Endometriosis
TTX334e
Undisclosed
Endometriosis
(non-hormonal)
Oncology
TTX335o
Undisclosed + Companion Biomarker
Recurrent, Sensitive & Platinum Resistant Ovarian Cancer
Screening, Diagnostic, and Companion Biomarkers
Breakthrough Screening, Diagnostic and Companion Biomarkers
.
Indication
Proof op Concept
& Feasibility
Design & Verification
Pivotal
Companion Diagnostic Biomarker-FDA 510K (De-Novo) & EMA CE-IVD
TTX334Dx
Endometriosis
TTX335Dx
Ovarian Cancer
Endometriosis –Lab Developed Test (Early Screen)
Indication
Proof op Concept
& Feasibility
Design & Verification
Pivotal
Endometriosis
Product
Target & MOA
Indication
Proof of Concept
& Feasibility
Design & Verification
Pivotal
IDE Filing
& Approval
Companion Diagnostic Biomarker-FDA 510K (De-Novo) & EMA CE-IVD
TTX334Dx
Undisclosed Biomarker
Diagnosis & Therapy Response for Endometriosis
TTX335Dx
Undisclosed Biomarker
Ovarian Cancer Screen & Therapy Response
Endometriosis –Lab Developed Test (Early Screen)
Product
Target & MOA
Indication
Proof of Concept
& Feasibility
Design & Verification
Pivotal
IDE Filing
& Approval
TTX334Dx
Undisclosed Biomarker
Endometriosis
Screen & Diagnosis
